![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Integrated Week 96 Subgroup Analyses
|
|
|
Reported by Jules Levin
IAS 2013 June 30-July 3 Kuala Lumpur
D Cooper1, A Zolopa2, JK Rockstroh3, C Orkin4, HJ Stellbrink5,
S Walmsley6, L Zhong7, M Fordyce7, MS Rhee7, J Szwarcberg7
1St Vincent's Hospital, Sydney, Australia; 2Stanford University, Palo Alto, CA, US; 3University of Bonn, Bonn, Germany; 4Barts and the London NHS Trust, London, UK; 5ICH Study Center, Hamburg, Germany;
6Toronto General Hospital, Toronto, Canada; 7Gilead Sciences, Foster City, CA, US
![IAS1.gif](../images/071013/071013-4/IAS1.gif)
![IAS2.gif](../images/071013/071013-4/IAS2.gif)
![IAS3.gif](../images/071013/071013-4/IAS3.gif)
![IAS4.gif](../images/071013/071013-4/IAS4.gif)
![IAS5.gif](../images/071013/071013-4/IAS5.gif)
![IAS6.gif](../images/071013/071013-4/IAS6.gif)
![IAS7.gif](../images/071013/071013-4/IAS7.gif)
![IAS8.gif](../images/071013/071013-4/IAS8.gif)
![IAS9.gif](../images/071013/071013-4/IAS9.gif)
![IAS10.gif](../images/071013/071013-4/IAS10.gif)
![IAS11.gif](../images/071013/071013-4/IAS11.gif)
![IAS12.gif](../images/071013/071013-4/IAS12.gif)
![IAS13.gif](../images/071013/071013-4/IAS13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|